Patients harboring exon 20 insertion mutations did considerably worse than the rest of the cohort with a TTD of 1.5 months, though the two patients with EGFR exon 20 insertion NSCLC who received osimertinib in the first-line setting had an average TTD of 8 months. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.